Table 3.
OR | 95% CI | P value | |
Days between onset and admission | 1 | 0.99 to 1.01 | 0.96 |
Age | 1.04 | 1.03 to 1.04 | <0.001 |
Male | 2.09 | 1.76 to 2.48 | <0.001 |
Comorbidities | |||
Cardiovascular disease | 1.48 | 1.04 to 2.10 | 0.028 |
Cerebrovascular disease | 1.33 | 0.95 to 1.85 | 0.097 |
Chronic respiratory disease | 2.51 | 1.67 to 3.78 | <0.001 |
Asthma | 1.24 | 0.87 to 1.77 | 0.24 |
Liver disease | 0.97 | 0.61 to 1.54 | 0.892 |
Diabetes | 1.34 | 1.09 to 1.64 | 0.006 |
Obesity diagnosed by physicians | 1.75 | 1.26 to 2.45 | 0.001 |
Severe renal disease or dialysis | 1 | 0.54 to 1.88 | 0.991 |
Solid tumour | 1.2 | 0.82 to 1.77 | 0.351 |
Leukaemia | 0.34 | 0.08 to 1.39 | 0.132 |
Lymphoma | 0.42 | 0.16 to 1.11 | 0.081 |
Hypertension | 1.33 | 1.08 to 1.64 | 0.008 |
Hyperlipidaemia | 0.91 | 0.70 to 1.19 | 0.49 |
Treatments prior to COVID-19 | |||
Use of steroid in 1 month | 1.65 | 0.52 to 5.22 | 0.394 |
Chemotherapy in 3 months | 1.47 | 0.72 to 3.0 | 0.286 |
Immunosuppressants* use in 3 months | 1.35 | 0.69 to 2.64 | 0.384 |
*Immunosupprenssants other than steroids.